Beyond Thinking
Welcome to Beyond Blue’s Thought Leadership Hub, where we highlight complex concepts with clarity and showcase our commitment to delivering excellence with ease. Explore our insights, discover innovative perspectives and join us on a journey to navigate the intricate with confidence.
Beyond the Bubble: How to reach and really understand rare disease patients
Researching rare diseases isn’t just about gathering data. It’s about honouring people’s stories, working with empathy, and designing research that genuinely reflects the realities of small, often overlooked groups of individuals. Here’s what we think really matters...
Breast Cancer 2026: Navigating the forks in the road
Author: Siobhan Davies, Research Consultant, Beyond Blue 2025 delivered a remarkable volume of breast cancer data, with striking results across multiple subtypes and treatment settings. As we move into 2026, these advances need to find their place, and physicians are...
If Your Strategy Needs Explaining, it’s Already Failed
Author: Beyond Blue Strategy Team What comes to mind when you think of the word strategy? Maybe you picture something heavy and abstract, a maze of frameworks, or a workshop full of swirling post-its, or a pensive-looking individual in a black rollneck? In reality,...
Mind the (Trust) Gap
Authors: Jenny Fletcher - Marketing Director, Mike Pepp - Senior Commercial Consultant, Sam Hope - CEO, Beyond Blue Over the holidays, an article caught our eye: Trust Gap: Why Patients Turn to TikTok Instead of Pharmaceutical Messaging by the Global Healthy Living...
The BTKi Rollercoaster in MS Continues to Surprise
Author: Nikita Shah, Beyond Neurology The rollercoaster in the MS fairground has taken another sharp turn. Tolebrutinib has missed its primary endpoint in the Phase 3 PERSEUS trial in PPMS, and the already delayed FDA decision for its nrSPMS indication now looks...
Using Behavior Change Models to Ensure a More Holistic Assessment of Health Conditions
Behavior Change models condense many years of research on the influences shaping our actions. In healthcare market research, there continues to be significant focus on COM-B, given its wide applicability. We should not, however, overlook the potential contribution of...
Multiple Myeloma at ASH 2025: Navigating a rapidly evolving landscape
The multiple myeloma (MM) landscape continues to evolve at a rapid pace. Key data presented at ASH spanned CAR-T therapies (long-term data from CARTITUDE-4, iMMagine-1), bispecific antibodies (MAJESTEC-3), antibody–drug conjugates (long-term data from DREAMM-7 &...
Cut the Clutter: How quantitative testing drives message precision
Too many messages, too little time. Brand teams often face a conveyor belt of messages and visuals, each one rolling past with its own merit, creative direction, and strategic grounding. But HCPs are time-poor, and in both testing and real-life sales, we have only...
Celebrating Culture and Connection: Manchester meetup
Author: Kelly Shipley, Head of Talent On 1st October, we did something special. We brought our global team together in person for the start of our annual networking and connection day. We met at our city centre venue in Manchester to connect, share, and identify...
